小牛血去蛋白注射液对高糖条件下坐骨神经慢性缺血的影响

目的:研究小牛血去蛋白注射液对高糖条件下坐骨神经慢性缺血的影响.方法:44只大鼠随机分为对照组、模型组、治疗组和脉络宁组,每组11只.除对照组外,其余3组大鼠尾静脉注射链脲佐菌素造成糖尿病模型,在此基础上结扎坐骨神经,形成一段神经的慢性缺血.前2组腹腔注射氯化钠注射液,后2组分别腹腔注射小牛血去蛋白注射液2.7mL·kg-1和脉络宁注射液1.8mL·kg-1,各组大鼠均在结扎坐骨神经后当天开始用药,qd,连续45d.测定体重、血糖、神经传导速度、神经组织中的山梨醇和ATP含量,并在光镜下观察神经的形态学改变,以评价疗效.结果:治疗组与模型组比较,神经传导速度、神经组织中ATP含量及形态学指标均有明显改变(P<0.05),而对山梨醇、血糖则无明显抑制作用(P>0.05).结论:小牛血去蛋白注射液对高糖条件下坐骨神经慢性缺血有明显的治疗作用.     

过氧化氢-乙醚法制备脱蛋白骨的理化性质研究

目的探讨过氧化氢-乙醚法制备脱蛋白骨（deproteinized bone，DPB）的理化性质。方法采用过氧化氢-乙醚法将大白兔干骺端松质骨脱脂、脱蛋白制作成生物衍生骨材料——DPB。倒置相差显微镜、体视学显微镜、扫描电子显微镜观察DPB材料外表面、孔隙内表面结构、孔径大小和孔间交通情况。pH计检测仪检测DPB材料的培养液pH值。光学显微镜观察微生物生长情况。微量凯氏定氮法检测DPB材料中蛋白质含量。结果倒置相差显微镜、体视学显微镜、扫描电子显微镜观察结果显示，DPB材料具有原骨组织的三维多孔一网架结构系统。计算机图像分析系统结果显示，孔隙率为（83．26±5．35）％；孔径最大径为（315．11±17．51）μm，最小径为（109．37±11．33）μm。浸泡DPB材料组培养液pH为7．383±0．015，空白对照组培养液pH为7．380±0．020。光学显微镜下观察结果显示，DPB材料的培养液未发现细菌或霉菌生长。DPB蛋白质含量为（20．4±1.2）％。结论由松质骨来源制作的DPB是一种较理想的组织工程骨生物支架材料。     

Grafting of deproteinized bone particles inhibits bone resorption after maxillary sinus floor elevation

OBJECTIVES: To evaluate the value of deproteinized bone particles on bone resorption in the augmented space after maxillary sinus floor elevation in rabbits. MATERIAL AND METHODS: A total of 20 rabbits underwent bilateral grafting, using blood clots (control group) and deproteinized bone particles (experimental group), and followed with histologic and histomorphometric analysis. RESULTS: Two weeks after grafting, the augmented space was almost completely obliterated by both newly formed bone and fibrous connective tissue in the control group. Some osteoclasts were found on the surface of newly formed bone, especially near the elevated sinus membrane. In the experimental group, newly formed bone was found along the elevated sinus membrane, the cortical wall of the augmented space, and the surface of deproteinized bone particles near the cortical wall. Some osteoclasts were found along the deproteinized bone particles and a few adhered to the surface of the newly formed bone. Eight to 10 weeks after implantation in the control group, most of the newly formed bone had been resorbed. In the experimental group, newly formed bone was found in most parts of the convex augmented space. Histomorphometrical analysis showed that the augmented height was significantly higher in the experimental group than in the control group at all evaluation times. Bone area was significantly higher in the experimental group than in the control group at 6, 8, and 10 weeks after implantation. The area of grafted deproteinized bone particles did not change significantly from 2 to 10 weeks. CONCLUSION: Slowly resorbed deproteinized bone particles contribute to stable augmentation of the maxillary sinus floor by inhibiting bone resorption.     

A randomized-controlled clinical trial evaluating clinical and radiological outcomes after 3 and 5 years of dental implants placed in bone regenerated by means of GBR techniques with or without the addition of BMP-2

Objective: The aim of this randomized-controlled clinical trial was to evaluate the long-term outcome of implants placed in bone augmented with a xenogenic bone substitute material and a collagen membrane with or without the addition of recombinant human bone morphogenetic protein-2 (rhBMP-2).
Material and methods: Eleven patients received a total of 34 implants placed into sites exhibiting lateral bone defects. In a split mouth design, the defects were randomly treated with the graft material and the collagen membrane either with (test) or without (control) rhBMP-2. The patients were examined 3 and 5 years after insertion of the prosthetic restoration. Student's paired t -test was performed to detect differences between the two groups.
Results: The survival rate at 3 and 5 years was 100% for both groups. The peri-implant soft tissues were stable and healthy without any difference between the two groups. The prosthetic reevaluation demonstrated four loose prosthetic screws during the first 3 years and seven ceramic chippings after 3 and 5 years. The mean distance between the first bone to implant contact to implant abutment junction at 3 years was 1.37 mm (test), 1.22 mm (control), and 1.38 mm (test), and 1.23 mm (control) at 5 years. The difference of <0.2 mm between test and control implants was not statistically significant. The mean change of the marginal bone level between baseline and 5 years ranged from −0.07 mm (mesial, test), −0.11 mm (distal, test), −0.03 mm (mesial, control), to +0.13 mm (distal, control). No statistically significant differences were observed between test and control sites.
Conclusion: Implants placed in bone augmented with and without rhBMP-2 revealed excellent clinical and radiological outcomes after 3 and 5 years.     

小牛血去蛋白提取物治疗缺血性脑梗死疗效分析

目的：探讨小牛血去蛋白提取物在缺血性脑梗死患者中的应用价值。方法：将66例缺血性脑梗死患者随机分为对照组和小牛血去蛋白提取物治疗组,治疗组33例予以小牛血去蛋白提取物30mL静脉滴注,1次/日,连续3周。对照组33例除未给予小牛血去蛋白提取物外其它治疗相同。对两组患者治疗前后血液流变学及神经功能缺损程度评分的变化情况进行比较分析。结果：小牛血去蛋白提取物治疗组显效率为72.7%,明显高于对照组（45.5%,P〈0.05）。治疗后小牛血去蛋白提取物治疗组全血黏度（低切）、红细胞压积和血小板聚集率均明显低于对照组（P〈0.05）,且均明显低于治疗前（P〈0.05）;而血浆黏度两组变化相近。治疗后小牛血去蛋白提取物治疗组的神经功能缺损程度评分明显低于对照组（P〈0.05）。结论：小牛血去蛋白提取物对缺血性脑梗死患者有确切疗效,未发现不良反应,可在临床推广。